Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion
NCT03206931
·
clinicaltrials.gov ↗
NO_LONGER_AVAILABLE
Status
INDUSTRY
Sponsor class
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
DRUG:
Selitrectinib (BAY2731954)
Sponsor
Bayer